Oblita
  • About us
    • Who we are
    • Our motivation
    • How we work
    • Contact us
  • Team
    • Management team
    • Scientific Advisory Board
    • Board of Directors
  • Product
    • D121
  • Global Health
    • Commitment
    • Priority Review Voucher
    • Leishmaniasis
    • Chagas Disease
    • Fungal infections
    • Cryptosporidium infection
  • Investors
  • News
Select Page

Welcome on Board of Directors

Oblita Therapeutics opens positions on its Board of Directors to any investor contributing to the further development of D121.

Investing in the further development of D121? Contact us.

© Oblita Therapeutics – global health research & development

TT4CL

  • Follow
  • Follow